

Product Name	: Sulfatinib
Synonyms	: HMPL-012; Surufatinib; HMPL012
Cat No.	: M11232
CAS Number	: 1308672-74-3
Molecular Formula	: C ₂₄ H ₂₈ N ₆ O ₃ S
Formula Weight	: 480.58
Chemical Name	: Benzenemethanesulfonamide, N-[2-(dimethylamino)ethyl]-3-[[4-[(2-methyl-1H-indol-5-yl)oxy]-2-pyrimidinyl]amino]-
Description	: Sulfatinib (HMPL-012) is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1/2/3, FGFR1, CSF1R with IC ₅₀ of 2/24/1 nM, 15 nM, 4 nM, respectively; also potently inhibits TrkB and FLT-3 with IC ₅₀ of 41 and 67 nM, shows little to no activity against other 278 other kinases (IC ₅₀ >150 nM); targets tumor angiogenesis and immune modulation, exhibits an acceptable safety profile and encouraging antitumor activity in clinical investigations. Brain Cancer Phase 3 Clinical
Pathway	: Angiogenesis
Target	: VEGFR
Receptor	: VEGFR
Solubility	: DMSO: ≥ 30 mg/mL
SMILES	: <chem>CC1=CC2=C(N1)C=CC(OC3=NC(NC4=CC(CS(NCCN(C)C)(=O)=O)=CC=C4)=NC=C3)=C2</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1. Xu JM, et al. Oncotarget. 2017 Jun 27;8(26):42076-42086.